| 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2026-016 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 股东及董高减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东及董高持股的基本情况 截至本公告披露日：公司董事、高级管理人员刘辉持有上海润达医疗科技股 份有限公司（以下简称"公司"、"润达医疗"）股份共计 31,528,771 股，占公司 总股本 5.22%。公司股东朱文怡持有公司股份共计 28,839,409 股，占公司总股本 4.78%。 减持计划的主要内容 公司股东朱文怡及刘辉拟在本公告之日起 15 个交易日后的三个月内通过大 宗交易或集中竞价交易方式减持股份。 | 股东 | 减持数量 | | 占公司总股份数 | | --- | --- | --- | --- | | 刘辉 | 不超过：7,460,000 | 股 | 不超过：1.24% | | 朱文怡 | ...

润达医疗公告称，截至公告披露日，董事、高管刘辉持股31,528,771股，占总股本5.22%；股东朱文怡 持股28,839,409股，占比4.78%，二者为母子关系。两人拟在15个交易日后的三个月内（2026年3月18日 至6月17日），通过大宗交易或集中竞价方式减持。刘辉拟减持不超7,460,000股（不超1.24%），朱文 怡拟减持不超10,540,000股（不超1.75%），减持原因均为个人资金需求。 ...

润达医疗公告，董事、高管刘辉持股3152.88万股，占5.22%，股东朱文怡持股2883.94万股，占4.78%； 两人拟于2026年3月18日～2026年6月17日期间，距公告15个交易日后，通过大宗交易或集中竞价方式减 持。刘辉拟减持不超过746万股，占1.24%；朱文怡拟减持不超过1054万股，占1.75%。 ...

Core Viewpoint - The announcement details the release of shareholdings from freezing for two shareholders, Liu Hui and Zhu Wenyi, which may have implications for the company's stock liquidity and shareholder structure [2][4]. Shareholder Information - Liu Hui holds 31,528,771 shares, representing 5.22% of the total share capital, with 9,000,000 shares released from freezing. Remaining frozen shares amount to 2,904,000, which is 9.21% of his holdings and 0.48% of the total share capital [2]. - Zhu Wenyi holds 28,839,409 shares, representing 4.78% of the total share capital, with 9,000,000 shares released from freezing. There are no remaining frozen shares [2]. - Liu Hui and Zhu Wenyi are acting in concert, collectively holding 60,368,180 shares, which is 10.00% of the total share capital, with a total of 2,904,000 shares frozen, accounting for 4.81% of their holdings and 0.48% of the total share capital [2]. Frozen Shares History - The shares of Liu Hui and Zhu Wenyi were frozen on January 5, 2026, as detailed in a previous announcement [2][3]. Impact on the Company - The release of shares from freezing is not expected to significantly impact the company's operations, as Liu Hui and Zhu Wenyi are not the controlling shareholders or actual controllers of the company [4].

一、本次解除冻结股份的原冻结情况 公司股东刘辉先生及朱文怡女士的部分股份于 2026 年 1 月 5 日被冻结，具 体内容详见公司披露的《股东股份冻结的公告》（编号：临 2026-006）。 二、本次解除冻结情况 | 证券代码：603108 | 证券简称：润达医疗 | 公告编号：临 2026-015 | | --- | --- | --- | | 转债代码：113588 | 转债简称：润达转债 | | 上海润达医疗科技股份有限公司 股东股份解除冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海润达医疗科技股份有限公司（以下简称"公司"）于今日获悉公司股东 刘辉先生和朱文怡女士的部分股份已解除冻结，具体情况如下： | 股东名称 | 持股数量 | 持股比例 | 累计被冻结 | 累计被 标记数 | 合计占其所 | 合计占公司 | | --- | --- | --- | --- | --- | --- | --- | | | （股） | | 数量（股） | 量（股） | 持股份比例 | 总股本比例 | | ...

Core Insights - The medical consumables supply chain SPD sector experienced a decline of 0.7% compared to the previous trading day, with Zhejiang Zhenyuan leading the drop [1] - The Shanghai Composite Index closed at 4134.02, up 0.05%, while the Shenzhen Component Index closed at 14283.0, up 0.86% [1] Sector Performance - The following companies in the medical consumables supply chain SPD sector showed varied performance: - RunDa Medical (603108) closed at 16.39, up 1.24% with a trading volume of 202,700 shares and a transaction value of 331 million yuan - JianMo Information (605186) closed at 22.28, up 0.22% with a trading volume of 27,300 shares and a transaction value of 60.93 million yuan - YingTe Group (000411) closed at 12.15, up 0.08% with a trading volume of 54,500 shares and a transaction value of 66.11 million yuan - Other companies like Langma Information (300288) and Guoyao Yizhi (000028) saw slight declines of 0.14% and 0.15% respectively [1] Capital Flow - On the same day, the medical consumables supply chain SPD sector saw a net outflow of 85.57 million yuan from institutional investors, while retail investors contributed a net inflow of 79.17 million yuan [2] - The capital flow for specific companies included: - RunDa Medical had a net inflow of 35.06 million yuan from institutional investors, while retail investors had a net outflow of 27.57 million yuan [3] - Zhejiang Zhenyuan experienced a net outflow of 0.82 million yuan from institutional investors, but a net inflow of 4.14 million yuan from retail investors [3]

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Group 1 - The core viewpoint of the news is that RunDa Medical has seen a stock price increase of 5.25%, reaching 16.85 CNY per share, with a total market capitalization of 10.172 billion CNY [1] - RunDa Medical, established on January 6, 1999, and listed on May 27, 2015, specializes in providing in vitro diagnostic products and professional technical support to various medical laboratories through its comprehensive service system [1] - The revenue composition of RunDa Medical includes 93.50% from reagents and other consumables, 3.70% from instruments, 2.67% from software development and services, and 0.14% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Dongcai has heavily invested in RunDa Medical, with the Dongcai Vision Growth Mixed Fund A (018088) increasing its holdings by 9,500 shares in the fourth quarter, making it the largest holding in the fund [2] - The Dongcai Vision Growth Mixed Fund A (018088) has a current scale of 10.8951 million CNY and has achieved a year-to-date return of 14.91%, ranking 432 out of 8,880 in its category [2] - The fund manager, Sun Chenyang, has been in position for 2 years and 307 days, with the best fund return during his tenure being 71.92% and the worst being -28.98% [3]

Core Viewpoint - RunDa Medical (603108.SH) has announced a projected net loss for 2025, estimating a loss between 5.65 billion to 4.71 billion yuan, reflecting significant operational challenges due to industry-wide price reductions and macroeconomic pressures [2][3] Financial Performance - The company's net profit for 2023 saw a year-on-year decline of 62.16%, with a further drop of 78.94% in 2024 [2] - For the first three quarters of 2025, the net profit was reported at -1.63 billion yuan, compared to a profit of 50.42 million yuan in the same period last year [2] - Overall revenue decreased by approximately 15% compared to the previous year [3] Industry Challenges - The IVD (in vitro diagnostics) sector is facing challenges due to centralized procurement policies that have led to price reductions, impacting revenue and profit margins [3][7] - The implementation of centralized procurement has resulted in lower product prices and delayed payment cycles from public hospitals, exacerbating financial pressures on the company [3][4] Subsidiary Performance - Some subsidiaries of RunDa Medical have not met profitability expectations, leading to an anticipated goodwill impairment provision of 180 million to 220 million yuan [4] - The company has noted that accounts receivable collection periods have lengthened due to financial pressures on hospitals, although the risk of bad debts remains low [4][5] Business Segments - RunDa Medical's business is divided into three main segments: commercial, industrial, and emerging AI medical services, all of which are experiencing varying degrees of pressure [6] - The commercial segment, which is the main revenue driver, reported a revenue decline of 8.34% in 2024, with further declines in specific areas such as centralized testing services and third-party laboratory services [6] Future Outlook - The company is focusing on AI medical and digital business as future growth areas, with the medical information business showing a 40.73% revenue increase in the first half of 2025 [8] - However, the new business segments are not expected to compensate for the decline in traditional business in the short term [8][9] - RunDa Medical plans to leverage its technological expertise in smart healthcare to enhance its service offerings and operational efficiency [9][10]

Core Viewpoint - RunDa Medical has announced a projected net loss for the fiscal year 2025, estimating a loss between 565 million yuan and 471 million yuan, a significant decline compared to a profit of 55.28 million yuan in the same period last year [1] Group 1: Financial Performance - The company's revenue is expected to decrease by approximately 15% compared to the same period last year due to changes in the domestic macro environment and the implementation of centralized procurement policies in the in-vitro diagnostics industry [1] - The gross profit margin has also experienced a decline, contributing to the overall expected loss [1] Group 2: Cost Management and Operational Challenges - In response to external environmental changes, the company has implemented various cost control and expense management measures to enhance operational efficiency [1] - Fixed costs such as depreciation, amortization, and financing expenses have not decreased in proportion to the revenue decline, impacting overall profitability [1] Group 3: Impairment and Receivables - The company anticipates recognizing goodwill impairment provisions between 180 million yuan and 220 million yuan based on the actual operating conditions of certain subsidiaries, with the final amount subject to audit and evaluation [1] - There has been an extension in the collection period for accounts receivable, leading the company to make credit impairment provisions for related receivables [1]